Syndecan-4 is Expressed by B Lineage Lymphocytes and Can Transmit a Signal for Formation of Dendritic Processes
Overview
Affiliations
Our previous studies indicated that stromal cell-derived syndecan-4 might mediate some form of communication with pre-B cells in bone marrow. We now report additional aspects of this recognition and show that syndecan-4 is also present on pre-B cells. Indeed, the molecule is acquired at an early stage of differentiation and retained until mature B cells undergo Ig isotype switching. mAbs developed to two portions of the syndecan-4 protein core were used to probe possible functions on B lineage lymphocytes. Syndecan-4 ligation had no obvious influence on B lymphocyte formation or activation, but this treatment caused a dramatic morphological change in appropriately stimulated leukocytes. Extended filopodia appeared on transfected Ba/F3 or FDCP-1 cells, as well as activated B cell blasts that were placed on syndecan-4 Ab-coated surfaces. The dendritic processes contained polymerized actin as well as pp52(LSP1), a prominent F-actin binding protein in lymphocytes. The cytoplasmic domain of syndecan-4 was not required for this response. Shape changes of this type could facilitate interactions between B lymphocytes and other components of the immune system. Not only is syndecan-4 a useful marker for discriminating normal B lineage lymphocyte subsets, but our results suggest new ways for the syndecans to participate in immune responses.
A translational perspective of the malignant hematopoietic proteoglycome.
Borghini N, Lazzaretti M, Lunghi P, Malpeli G, Barbi S, Perris R Cell Biosci. 2025; 15(1):25.
PMID: 39980017 PMC: 11844096. DOI: 10.1186/s13578-025-01360-7.
Vercellino J, Malachowska B, Kulkarni S, Bell B, Shajahan S, Shinoda K Stem Cell Res Ther. 2024; 15(1):123.
PMID: 38679747 PMC: 11057170. DOI: 10.1186/s13287-024-03734-z.
Vercellino J, Malachowska B, Kulkarni S, Bell B, Shajahan S, Shinoda K Res Sq. 2024; .
PMID: 38463959 PMC: 10925435. DOI: 10.21203/rs.3.rs-3946910/v1.
GPNMB: a potent inducer of immunosuppression in cancer.
Lazaratos A, Annis M, Siegel P Oncogene. 2022; 41(41):4573-4590.
PMID: 36050467 DOI: 10.1038/s41388-022-02443-2.
Ali M, Dasari H, Van Keulen V, Cornec D, Vasmatzis G, Peikert T Sci Rep. 2017; 7(1):3869.
PMID: 28634370 PMC: 5478602. DOI: 10.1038/s41598-017-04199-2.